StockData

Adaptive Biotechnologies vs Iovance Biotherapeutics

ADPT and IOVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADPT and IOVA compare

Adaptive Biotechnologies is the larger company, worth 1.3 times as much as Iovance Biotherapeutics ($4.5B against $3.4B).

Adaptive Biotechnologies grew revenue faster over the last twelve months (50.1% versus 34.5% for Iovance Biotherapeutics).

Adaptive Biotechnologies keeps more of each dollar of sales as profit, with a net margin of −20.7% compared with −89.1% at Iovance Biotherapeutics.

Adaptive Biotechnologies scores higher on the StockData Score (12 against 9 for Iovance Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADPTIOVA
Size and price
Market cap$4.5B$3.4B
Share price$28.49$7.53
Change, 1 year102%205%
Change, 5 years1.3%−59.3%
Beta (5Y)0.511.45
Employees624975
StockData Score
Total score12 (better)9
Valuation score00
Growth score4 (better)2
Performance score3 (better)1
Health score56 (better)
Dividend score00
Valuation
P/S14.8×10.5× (better)
P/B31.8×4.6× (better)
FCF yield−0.53% (better)−8.7%
Fair value–$4.03
Margin of safety–−86.8%
Growth
Revenue growth (TTM)50.1% (better)34.5%
Revenue growth, 5Y average23.0%–
Profitability
Gross margin75.6% (better)48.4%
Operating margin−12.2% (better)−92.7%
Net margin−20.7% (better)−89.1%
FCF margin−7.8% (better)−91.2%
Return on equity−39.6% (better)−40.4%
Return on invested capital–−57.0%
Financial health
Debt / equity0.000.00
Interest coverage−3.3×–
Current ratio4.79 (better)4.35
Altman Z-score3.376.70 (better)
Piotroski F-score5 (better)4
Dividends and buybacks
Buyback yield–−8.6%
Shareholder yield0.00% (better)−8.6%
Ownership
Held by institutions97.6%63.3%
Held by insiders22.7%0.39%
Insider net buying, 12 months−$118M–
Superinvestors holding1–
Short interest, % of float9.3%14.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.